TLMdX from AASLD 2020

November 13—16, 2020

While we are gathering our agenda, we invite you to subscribe to be notified when this event page is available

Saturday, Nov 14, 2020

Our Surfers Discussed The Following Papers and Sessions on Day 2

Today’s Episode Is Sponsored By

Roger Green — 1662
ASSESSMENT OF PATIENT-REPORTED OUTCOMES IN A LARGE COHORT OF NASH PATIENTS WITHOUT CIRRHOSIS — ZOBAIR YOUNOSSI

Donna Cryer —  0060
CLINICIAL CHARACTERISTICS USED FOR MACHINE LEARNING IDENTIFICATION OF FAST PROGRESSORS AMONG PATIENTS WITH NASH — JOERN SCHATTENBERG.

Louise Campbell MSc AP — 0056 NONINVASIVE ASSESSMENTS TO IDENTIFY PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: SCREENED POPULATION FROM THE REGENERATE TRIAL — JEROME BOURSIER

Dr. Stephen Harrison — 1710 A 52-WEEK MULTI-CENTER DOUBLE-BLIND RANDOMIZED PHASE 2 STUDY OF SELADELPAR, A POTENT AND SELECTIVE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA (PPAR-DELTA) AGONIST, IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)

Manal F. Abdelmalek — 0057
GEMS, A Genetic Metabolic Staging Predicting the Outcome of NAFLD — GRAZIA PENNISI

Sonic Incytes is on a mission to reduce chronic liver disease by enabling routine assessment and management of liver health. Its breakthrough, point of care ultrasound solution, Velacur™, assesses and manages chronic liver disease with diagnostic accuracy that is comparable to MRI. Learn more: www.sonicincytes.com

Surfing The NASH Tsunami Podcast Day 2

Sunday, Nov 15, 2020

Our Surfers Discussed The Following Papers and Sessions on Day 3

Louise Campbell MSc AP — 0090 CIRRHOSIS REGRESSION IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)

Roger Green & Louise Campbell MSc AP — 0086 THE NATURAL HISTORY OF LEAN NONALCOHOLIC FATTY LIVER DISEASE: A LONGITUDINAL US POPULATION STUDY

Roger Green — 072 FINAL ANALYSIS OF A 24-WEEK, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ALDAFERMIN (NGM282) IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS

Mazen Noureddin — 008 EFRUXIFERMIN (EFX), A LONG-ACTING FC-FGF21 FUSION PROTEIN, ADMINISTERED FOR 16 WEEKS TO PATIENTS WITH NASH, SUBSTANTIALLY REDUCES LIVER FAT AND ALT AND IMPROVES LIVER HISTOLOGY, ANALYSIS OF A RANDOMIZED, PLACEBO CONTROLLED PHASE 2A STUDY
Naim Alkhouri, M.D. — LO2 SAFETY AND EFFICACY OF COMBINATION THERAPIES INCLUDING SEMAGLUTIDE, CILAFEXOR AND FIRCOSTAT IN PATIENTS WITH NASH

Surfing The NASH Tsunami Podcast Day 3

Monday, Nov 16, 2020

Our Surfers Discussed The Following Papers and Sessions on Day 4

Dr. Stephen Harrison — LP23

RESOLVE-IT PHASE 3 TRIAL OF ELAFIBRANOR IN NASH: FINAL RESULTS OF THE3 WEEK 72 ITNERIM SURROGATE EFFICACY ANALYSIS

Louise Campbell MSc AP — 141

DIET RELATED MORTALITYARY AMONG NONALCOHOLIC FATTY LIVER DISEASE (NAFLD): DATA FROM THE GLOBAL BURDEN OF DISEASE (GBD) 2017

Roger Green — 

L03 – ALDAFERMIN  (NGM282) PRODUCES GREATER ANTI-FIBROTIC RESPONSE IN PATIENTS WITH  NONALCOHOLIC STREATOHEPATITIS AND ADVANCED FIBROSIS

&

0143
ONSET OF OBESITY-RELATED PEDIATRIC NONALCOHOLIC FATTY LIVER DISEASE (PNAFLD) DURING PREPUBERTAL GROWTH EXACERBATES HEPATIC INFLAMMATION AND MITOCHONDRIAL DNA DEPLETION TO ACCELERATE LIVER INJURY

Mary E. Rinella, MD. — 010

EFFICACY AND SAFETY OF SUBCUTANEOUS SEMAGLUTIDE ONCE-DAILY VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS

Surfing The NASH Tsunami Podcast Day 4

Episode 38

The Day After TLMdX 2020: Wrapping Up with The View from Across the Atlantic

Prof. Dr. Jörn M. Schattenberg and Vlad Ratziu join the Surfers for our wrap-up episode for TLMdX 2020. Joern focuses on a diabetes poster demonstrating the path of drug efficacy over a three-year period, while Vlad focuses on the successful Phase 2 trial of the pan-PPAR lanifibranor. The group also asks why placebo response varies so much between studies and whether the ratio of F2:F3 patients may be a factor. Finally, the Surfers focuses on what they consider the biggest lessons emerging from the meeting.

Available In Your Favorite Podcast App:

Apple
Spotify
Google
Stitcher
SoundCloud
YouTube
Buzzsprout